Squarepoint
XFOR icon

Squarepoint’s X4 Pharmaceuticals XFOR Stock Holding History

Squarepoint’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,518
Closed -$50.1K – 5081
2025
Q4 		$50.1K Buy
+12,518
New +$45.5K ﹤0.01% 4131
2025
Q3 		– Sell
-38,982
Closed -$74.1K – 5090
2025
Q2 		$74.1K Buy
+38,982
New +$160K ﹤0.01% 4235
2024
Q1 		– Sell
-2,159
Closed -$54.3K – 4688
2023
Q4 		$54.3K Buy
+2,159
New +$52.5K ﹤0.01% 3838
2021
Q3 		– Sell
-688
Closed -$134K – 3490
2021
Q2 		$134K Sell
688
-15
-2% -$3.77K ﹤0.01% 2959
2021
Q1 		$181K Buy
703
+131
+23% +$34.4K ﹤0.01% 2736
2020
Q4 		$110K Buy
572
+171
+43% +$33.6K ﹤0.01% 2704
2020
Q3 		$81K Sell
401
-309
-44% -$74.1K ﹤0.01% 2319
2020
Q2 		$199K Buy
+710
New +$194K ﹤0.01% 1825
2020
Q1 		– Sell
-456
Closed -$146K – 2603
2019
Q4 		$146K Buy
+456
New +$164K ﹤0.01% 2289
2019
Q1 		– Sell
-193
Closed -$81K – 2476
2018
Q4 		$81K Buy
193
+104
+117% +$39.7K ﹤0.01% 1817
2018
Q3 		$26K Buy
+89
New +$37.7K ﹤0.01% 1938

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Squarepoint's XFOR Position: Q1 2026 in Review

Squarepoint sold out of X4 Pharmaceuticals (XFOR) in Q1 2026, closing a stake of 12,518 shares — an estimated $50.1K sold.

Squarepoint first reported a position in XFOR in Q3 2018 and held it in 11 quarters. The position peaked at $199K in Q2 2020. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Squarepoint reported no remaining X4 Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 12,518 X4 Pharmaceuticals shares in Q1 2026, an estimated $50.1K.
  • Squarepoint first reported a position in X4 Pharmaceuticals in Q3 2018 and held it in 11 quarters.
  • Squarepoint's X4 Pharmaceuticals position peaked at $199K in Q2 2020.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.